Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab

ABP 980 was developed as a biosimilar to trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), that is indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. ABP 980 is approved in the U...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolberg, Hans-Christian, Colleoni, Marco, Santi, Patricia, Demetriou, Georgia Savva, Segui-Palmer, Miguel Angel, Fujiwara, Yasuhiro, Hurvitz, Sara A., Hanes, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875516/
https://www.ncbi.nlm.nih.gov/pubmed/31620980
http://dx.doi.org/10.1007/s11523-019-00675-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875516/
https://www.ncbi.nlm.nih.gov/pubmed/31620980
http://dx.doi.org/10.1007/s11523-019-00675-z

Ejemplares similares